Cathie Wood's Big Bet on Future Medicine

Cathie Wood, a well-known investor, made a significant move on the last trading day of 2025. She invested $1. 33 million in Intellia Therapeutics, a company focused on gene editing. This investment is notable because Intellia's stock has not performed well this year, dropping by 22%. Despite this, Wood sees potential in the biotech sector, particularly in gene editing, which she believes could revolutionize medicine. Gene editing is a cutting-edge field that aims to fix genetic problems at their source, rather than just treating symptoms. Intellia Therapeutics uses a technology called CRISPR, which acts like molecular scissors to correct DNA errors. The company is working on therapies that can be directly administered into the body to edit genes in vital organs like the liver. Intellia has shown promising results in clinical trials, but there are also risks, such as safety concerns and regulatory hurdles.Wood's investment strategy often involves betting on innovative technologies before they become mainstream. She has a track record of successful investments, including early bets on Tesla, Block (formerly Square), and Shopify. Her focus on gene editing reflects her belief that this technology could have a profound impact on healthcare and the economy. For instance, curing diseases like cancer could significantly reduce long-term healthcare costs. Intellia Therapeutics had a mixed year in 2025. While it made progress in some areas, such as showing durability in a treatment for a rare genetic disorder, it also faced setbacks. A serious liver event led to a pause in dosing and an FDA clinical hold on two late-stage studies. Despite these challenges, Intellia has a strong financial position, with sufficient cash to fund operations into mid-2027. The company's revenue is expected to grow significantly in the coming years, reaching an estimated $2. 35 billion by 2030.